Cristina Jimenez-Nieto

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Corrigendum to "Antitumoral activity of a CDK12 inhibitor in colorectal cancer through a liposomal formulation" [Biomed. Pharmacother. 178 (2024) 117165].

Corrigendum to "Antitumoral activity of a CDK12 inhibitor in colorectal cancer through a liposomal formulation" [Biomed. Pharmacother. 178 (2024) 117165].

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: April 22, 2026

Identification of Deregulated Proteins in Mutated BRCA1/2 Breast and Ovarian Cancers for Vectorized Biologics.

Identification of Deregulated Proteins in Mutated BRCA1/2 Breast and Ovarian Cancers for Vectorized Biologics.

Journal: Cancers

Published: May 23, 2025

Understanding the Toxicity Profile of Approved ADCs.

Understanding the Toxicity Profile of Approved ADCs.

Journal: Pharmaceutics

Published: January 11, 2025

DrugAppy - An end-to-end deep learning framework for computational drug discovery.

DrugAppy - An end-to-end deep learning framework for computational drug discovery.

Journal: Computers in biology and medicine

Published: November 26, 2024

Overcoming limitations for antibody-based therapies targeting γδ T (Vg9Vd2) cells.

Overcoming limitations for antibody-based therapies targeting γδ T (Vg9Vd2) cells.

Journal: Frontiers in immunology

Published: May 13, 2024

In silico evaluation of the immunogenic profile of lung cancers with SMARCA4 genetic alterations.

In silico evaluation of the immunogenic profile of lung cancers with SMARCA4 genetic alterations.

Journal: Scientific reports

Published: April 24, 2024

Clinical and Immunologic Characteristics of Colorectal Cancer Tumors Expressing LY6G6D.

Clinical and Immunologic Characteristics of Colorectal Cancer Tumors Expressing LY6G6D.

Journal: International journal of molecular sciences

Published: April 09, 2024

Antitumoral activity of a CDK12 inhibitor in colorectal cancer through a liposomal formulation.

Antitumoral activity of a CDK12 inhibitor in colorectal cancer through a liposomal formulation.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: March 27, 2024

In Silico Transcriptomic Expression of MSR1 in Solid Tumors Is Associated with Responses to Anti-PD1 and Anti-CTLA4 Therapies.

In Silico Transcriptomic Expression of MSR1 in Solid Tumors Is Associated with Responses to Anti-PD1 and Anti-CTLA4 Therapies.

Journal: International journal of molecular sciences

Published: March 05, 2024

Genomic and Immunologic Correlates in Prostate Cancer with High Expression of KLK2.

Genomic and Immunologic Correlates in Prostate Cancer with High Expression of KLK2.

Journal: International journal of molecular sciences

Published: November 29, 2023

Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned.

Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned.

Journal: Journal of hematology & oncology

Published: October 17, 2023

Guanylation Reactions for the Rational Design of Cancer Therapeutic Agents.

Guanylation Reactions for the Rational Design of Cancer Therapeutic Agents.

Journal: International journal of molecular sciences

Published: August 17, 2023

Showing 1-12 of 37

Last Updated: 09/26/2026